Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.
Open Access
- 15 July 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2600021
Abstract
Tumor comprehensive genomic profiling (CGP) has revolutionized cancer care and identifies patients for biomarker-specific therapy. In metastatic hormone-sensitive prostate cancer (mHSPC), although individual genes are prognostic, no comprehensive genomic classification exists using CGP that accounts for combinations of alterations to inform prognosis. We developed a DNA-based CGP classification that is prognostic for overall survival (OS) and could inform treatment. This was a retrospective cross-sectional study using multivariable models to develop a clinicogenomic prognostic risk classification in US veterans with synchronous mHSPC. The primary outcome was OS from time of metastasis. A total of 7,201 veterans with metastatic prostate cancer and CGP were identified. There were 2,484 veterans (median [IQR] age, 72 [67-77] years) with synchronous mHSPC and tissue CGP, which were divided into training and testing data sets. Sixteen genes associated with survival were identified, and favorable, intermediate, and unfavorable genomic prognostication groups were created based on the mortality risk to generate the Somatic Tumor Risk Assessment for OS-Prostate (STRATOS-P) classification. In a multivariable model, classification into intermediate and unfavorable groups was associated with increased mortality relative to the favorable group (adjusted hazard ratio [aHR], 1.54 [95% CI, 1.33 to 1.78]; aHR, 2.37 [95% CI, 1.97 to 2.485], respectively), demonstrating an average AUC of 0.83. In an external, nonveterans validation cohort, intermediate and unfavorable classifications were associated with increased mortality (aHR, 2.45 [95% CI, 1.87 to 3.21]; aHR, 4.37 [95% CI, 3.06 to 6.22], respectively) with an AUC of 0.79. The intermediate and unfavorable genomic prognostication groups were also associated with increased mortality across multiple disease states including synchronous and metachronous diagnoses, castration resistance, and analyte type. In metastatic prostate cancer, tumor DNA genomic alterations are prognostic for OS. The STRATOS-P classification is a validated prognostic tool that has the potential to guide decision making in mHSPC.Keywords
This publication has 41 references indexed in Scilit:
- Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate CancerJAMA Network Open, 2025
- Treatment Patterns and Survival Among Veterans With De Novo Metastatic Hormone-Sensitive Prostate CancerJAMA Network Open, 2025
- Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate CancerJAMA Oncology, 2024
- Survival in Patients With De Novo Metastatic Prostate CancerJAMA Network Open, 2024
- Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016JAMA Network Open, 2021
- Genomic Hallmarks and Structural Variation in Metastatic Prostate CancerCell, 2018
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- The CAPRA‐S scoreCancer, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998